Key Takeaways
- CRISPR Therapeutics is the company behind Casgevy, the first FDA-approved CRISPR therapy (December 2023), partnered with Vertex on a 60/40 economic split.
- The workforce is ~600 people, split between a Zug, Switzerland registered HQ and a Boston-area R&D and operations hub; most scientific and clinical roles are in the US.
- The ATS is primarily Greenhouse (boards.greenhouse.io/crisprtherapeutics) with some Workday overlap on European and corporate roles — verify before tailoring.
- For scientific roles a PhD in molecular biology or an adjacent field is effectively required; clinical roles require cell-and-gene-therapy or ATMP trial experience.
- Boston base salaries for mid-career scientific and clinical roles typically run $160K to $280K plus RSU and option grants on CRSP stock; Zug ranges roughly CHF 120K to CHF 200K for equivalent levels.
- The interview bar is high and scientific — journal-club deep dives, mechanistic questioning, and cross-functional panels are standard; expect to defend your work against literature-current interviewers.
- Offer-decline losses to Vertex, Moderna, Editas, Beam, Intellia, and Verve are common, so prepare a specific, honest 'why CRISPR Therapeutics' answer that is not generic enthusiasm for gene editing.
- The company ended 2024 with roughly $1.9 billion in cash, offering multi-year runway — but commercial ramp on Casgevy is slow by design and the next pipeline catalysts matter for long-term career upside.
- Honest risk framing — slow Casgevy launch, competitive editing landscape, second-product execution risk — is welcomed in interviews and signals maturity rather than disloyalty.
About CRISPR Therapeutics
CRISPR Therapeutics AG (Nasdaq: CRSP) is a Swiss-American gene-editing biotechnology company founded in 2013 by Nobel laureate Emmanuelle Charpentier along with Rodger Novak and Shaun Foy, built around the foundational CRISPR/Cas9 intellectual property Charpentier would go on to share the 2020 Nobel Prize in Chemistry for discovering alongside Jennifer Doudna. The company maintains its registered headquarters in Zug, Switzerland — chosen for proximity to Basel-area pharma talent and the Swiss IP regime — while operating its primary research, clinical, and manufacturing footprint out of Boston (with major sites in Cambridge and Framingham, Massachusetts). As of 2025, CRISPR Therapeutics employs roughly 600 people split across these two hubs, with a smaller commercial presence expanding alongside its launch operations. The defining moment in the company's history came in late 2023, when exagamglogene autotemcel — branded Casgevy — received FDA approval on December 8, 2023 for sickle cell disease and on January 16, 2024 for transfusion-dependent beta-thalassemia, making it the first CRISPR-based therapy ever approved for human use and one of the most consequential biotech milestones of the decade. Casgevy is partnered with Vertex Pharmaceuticals under a 60/40 economic split favoring Vertex, which leads global commercialization and manufacturing while CRISPR Therapeutics books its share of profits and losses. The commercial ramp has been deliberately slow: because Casgevy requires specialized authorized treatment centers, bone-marrow conditioning, and a complex apheresis-to-infusion workflow that can take months per patient, Vertex reported only a handful of patients dosed in the first year of launch, with revenue recognition lagging well behind the scientific accomplishment. Beyond Casgevy, CRISPR Therapeutics' pipeline has pivoted aggressively toward in vivo editing and cell therapy programs outside hemoglobinopathies: CTX310 and CTX320 are in vivo lipid-nanoparticle-delivered editors targeting ANGPTL3 and LPA respectively for cardiovascular disease; the allogeneic CAR-T franchise (CTX112 targeting CD19, CTX131 targeting CD70) is advancing in oncology and autoimmune indications; and the regenerative medicine collaboration with ViaCyte (now owned by Vertex) on VCTX210 and VCTX211 explores CRISPR-engineered beta cells for Type 1 diabetes. Samarth Kulkarni, who joined from McKinsey in 2015 and was promoted to CEO in 2017, leads the company alongside CFO Raju Prasad, CMO Naimish Patel, and CSO William Lundberg. The balance sheet remains a core strategic asset: following Casgevy milestone payments and disciplined spending, CRISPR Therapeutics ended 2024 with roughly $1.9 billion in cash, cash equivalents, and marketable securities, giving the company a multi-year runway to execute on its in vivo and oncology pipeline without immediate dilution pressure — a rare luxury in a clinical-stage biotech landscape where competitors including Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Verve Therapeutics, and Prime Medicine are all racing for the next editing-modality breakthrough.
ATS System: Greenhouse
CRISPR Therapeutics has historically used Greenhouse for the majority of its external job postings, reachable via boards.greenhouse.io/crisprtherapeutics. Some roles (particularly European corporate positions) may surface on Workday-backed systems; always verify the apply URL on crisprtx.com/careers before tailoring formatting.
- Submit as .docx or text-based PDF — scanned image PDFs parse poorly in Greenhouse.
- Use standard section headers (Experience, Education, Skills, Publications). Avoid multi-column layouts that can scramble field extraction.
- Fill in every optional field on the application form — work-authorization, location, and self-identification fields feed recruiter filters.
- Attach a cover letter even when marked optional for scientific and clinical roles; hiring managers read them.
- Do not use tables or text boxes for key content — ATS parsers drop them inconsistently and reviewers may see blank sections.
Interview Culture
CRISPR Therapeutics interviews feel different depending on which site you are interviewing with, and candidates who miss this distinction often stumble.
The Boston R&D culture is fast, informal, and intensely scientific — expect journal-club-style sessions where you defend your published work against pointed mechanistic questions, whiteboard experiments on off-target prediction or delivery optimization, and cross-functional panels where a CMC engineer and a clinician both probe how your work would land in their domain. People wear jeans, coffee is ubiquitous, and debates about Cas variants or guide-RNA chemistry spill into hallways. The Zug culture is somewhat more formal, reflecting Swiss corporate norms and the corporate-functions concentration there: expect structured competency interviews, more attention to process and documentation, and a quieter-but-equally-rigorous style of scientific questioning for the research roles based in Europe. Across both sites, the bar on scientific rigor is unambiguously high — interviewers are former Broad, MIT, Harvard, ETH, EPFL, and top-pharma people, and they read the literature in their programs weekly. Several themes recur in candidate debriefs: first, everyone you meet will want to understand your 'why CRISPR Therapeutics specifically' answer, because offer-decline rates to Vertex, Moderna, Editas, Beam, and Intellia are tracked and hiring managers have become skilled at detecting shopping-around. Second, the post-Casgevy commercialization uncertainty is a real topic in interviews at every level — the company has proven it can edit the human genome and get approved, but the slow launch ramp, the 60/40 economic split with Vertex, and the question of whether in vivo programs can deliver a second approved therapy before cash burns meaningfully are things thoughtful candidates ask about, and interviewers respect directness rather than avoidance. Third, the small-company cross-functional chemistry evaluation is explicit: you will meet people outside your discipline, and their veto carries weight. Prepare to discuss not only the technical work but how you partner, communicate uncertainty, and handle program-level setbacks — because in a biotech this size, individual brilliance without collaborative range gets filtered out.
What CRISPR Therapeutics Looks For
- Deep, specific expertise in gene editing, molecular biology, cell therapy, or an adjacent scientific discipline — generalists rarely succeed in scientific roles.
- A track record of shipping — completed trials, filed INDs, published papers, released manufacturing campaigns — rather than projects that perpetually 'almost worked.'
- Comfort with ambiguity and program-level setbacks; clinical-stage biotech is a portfolio business and resilience is screened for.
- Cross-functional communication skills — the ability to brief a non-scientist partner, write a crisp regulatory memo, or defend a position to a clinical-development head.
- A clear, honest articulation of why CRISPR Therapeutics over Vertex, Moderna, Editas, Beam, Intellia, or Verve — recruiters and hiring managers probe this directly.
- For Boston roles: willingness to work on-site or in a hybrid model with meaningful in-person presence; the culture is collaborative and proximity-dependent.
- For Zug roles: ability to navigate Swiss corporate norms, European regulatory frameworks, and (ideally) prior European pharma experience.
- Alignment with the mission — the company recruits hard on the 'first CRISPR-approved therapy' story and measures long-term commitment to editing science as a durable career.
Frequently Asked Questions
What does CRISPR Therapeutics pay for mid-level scientific roles in Boston?
Based on publicly reported ranges and market data for comparable Cambridge and Framingham biotech employers, mid-career scientific roles (senior scientist, associate director, principal scientist) typically land between $160,000 and $280,000 in base salary, with target bonus of 15 to 25 percent and meaningful RSU plus option grants on CRSP stock. Clinical development and regulatory directors trend toward the upper half of that band, while bench-heavy research roles cluster in the middle. Total compensation including equity can exceed $400,000 for director-and-above roles in strong stock years, though CRSP volatility makes realized equity value highly variable.
What about Zug, Switzerland compensation?
Zug corporate and scientific roles generally pay between CHF 120,000 and CHF 200,000 in base salary for mid-career levels, with cash bonuses of 10 to 25 percent and equity grants in CRSP. Swiss compensation is typically structured with a 13th-month payment, mandatory social contributions, and employer pension funding that are not directly comparable to US packages. Cost of living in Zug is high but personal income tax rates are lower than most US metros, so on an after-tax basis the Zug ranges are competitive with Boston equivalents despite nominally lower headline numbers.
Why do offers often get declined in favor of Vertex, Moderna, Editas, or Beam?
The honest answer is that editing-talent is small and competitive. Vertex offers the balance-sheet stability of a commercial cystic-fibrosis franchise and Casgevy itself. Moderna offers platform breadth, cash, and broader mRNA career mobility. Editas, Beam, Intellia, and Verve compete directly on editing-modality differentiation (base editing, prime editing, in vivo delivery) and sometimes offer earlier equity or broader program ownership. Candidates who decline CRISPR Therapeutics offers usually cite one of: larger equity upside elsewhere, a modality they find more scientifically compelling, a specific program lead or mentor at a competitor, or concerns about Casgevy's slow commercial ramp. The company's counter-pitch is pedigree — the first approved CRISPR therapy is a durable credential — plus a strong cash position and a deep in vivo and oncology pipeline.
Is Casgevy actually generating meaningful revenue?
Not yet, and interviewers will not pretend otherwise. Casgevy launched in late 2023 and early 2024 in the US, UK, EU, and Saudi Arabia, but the treatment requires authorized treatment centers, bone-marrow conditioning, apheresis, ex vivo editing, and infusion — a months-long per-patient process. Vertex, which leads commercialization, has reported only a modest number of patients dosed in the first year, with revenue recognition meaningfully lagging. The ramp is expected to accelerate as more treatment centers come online and payer coverage stabilizes, but anyone joining should model a multi-year trajectory rather than expecting a fast launch curve.
How is CRISPR Therapeutics' cash position and runway?
Strong by clinical-stage biotech standards. Following Casgevy milestone payments from Vertex and disciplined spending, the company ended 2024 with approximately $1.9 billion in cash, cash equivalents, and marketable securities. At current burn rates driven by the in vivo cardiovascular programs, the allogeneic CAR-T franchise, and the regenerative-medicine work, that runway extends multiple years. This is a genuine strategic advantage — the company can execute on its pipeline without immediate dilution pressure, which matters for employees whose equity grants can be meaningfully diluted by emergency financings at competitors.
Do I need a PhD to work at CRISPR Therapeutics?
For principal scientist and above in research, effectively yes — a PhD in molecular biology, biochemistry, genetics, immunology, cell biology, bioengineering, or a closely adjacent field plus postdoctoral or strong industry experience is the norm. For MS-level research associate and senior research associate roles, a master's with strong hands-on expertise suffices. Clinical development, regulatory, CMC, commercial, and G&A roles do not require a PhD — an MD, PharmD, or MS is typical for clinical and regulatory; an MBA or relevant advanced degree is common for commercial and corporate functions.
How much do I need to know about Casgevy specifically before interviewing?
A lot. Before any interview, read the Casgevy FDA label, the 2021 and 2023 New England Journal of Medicine publications on exa-cel in sickle cell and beta-thalassemia, and at least skim the Vertex earnings call commentary on the launch. You do not need to be a hemoglobinopathy expert unless interviewing for that program, but you should be able to articulate the mechanism (BCL11A enhancer editing to reinduce fetal hemoglobin), the trial design, the conditioning regimen context, and why the commercial launch is slower than a small-molecule would be. Interviewers notice when candidates have only a generic 'first CRISPR therapy' awareness versus genuine engagement with the science.
What is the work-from-home policy?
CRISPR Therapeutics operates as a hybrid on-site company, reflecting the reality that bench science, clinical coordination, and manufacturing all require physical presence. Most roles expect meaningful in-person presence (typically three or more days per week) at the Boston-area sites or Zug. Fully remote roles exist but are rare and concentrated in specialized functions — some regulatory, medical affairs, field-based commercial roles, and certain computational or data-science positions. Ask the recruiter specifically about the team's expectation rather than assuming from the job posting.
How should I answer 'why CRISPR Therapeutics' in the interview?
The wrong answer is generic enthusiasm for CRISPR or gene editing — interviewers hear this constantly and it signals shopping-around. The right answer is specific to the company and the role: reference a particular program (CTX112, CTX310, CTX320, VCTX211) and explain why that science draws you, or connect to the Casgevy launch as a credential you want to be part of continuing, or name a leader, program lead, or prior publication from the company that influenced your path. Honest acknowledgment of the competitive landscape — 'I also looked at Beam and Intellia, and I chose this conversation because X' — plays better than pretending competitors do not exist.
Is the company sponsoring visas?
For Boston-based roles, CRISPR Therapeutics has historically sponsored H-1B, O-1, and green-card transfers for specialized scientific and clinical hires, though sponsorship depends on role level and is not universal — entry-level positions are less likely to receive sponsorship than director-and-above scientific hires. For Zug-based roles, Swiss work permits for non-EU/EFTA citizens are constrained by quota and typically require demonstrating that the role cannot be filled locally — the process takes four to twelve weeks beyond offer acceptance. Always confirm sponsorship explicitly with the recruiter during the initial screen rather than assuming.
Open Positions
CRISPR Therapeutics currently has 2 open positions.
Related Resources
Similar Companies
Related Articles
- ATS & Resume Keywords FAQ: 15 Questions About Getting Past the Bots
- Remote Social Media Manager Resume: Build Communities from Anywhere in 2026
- The Complete Guide to Skills-First Resumes (2026)
- Skills-First Resume for Tech: Migration Guide with Examples
- Remote UX/UI Designer Resume: Design from Anywhere in 2026
Sources
- CRISPR Therapeutics official careers site — CRISPR Therapeutics AG
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (Casgevy approval announcement, December 8, 2023) — U.S. Food and Drug Administration
- FDA Approves First Cell-Based Gene Therapy for Transfusion-Dependent Beta Thalassemia (Casgevy, January 16, 2024) — U.S. Food and Drug Administration
- The Nobel Prize in Chemistry 2020 — Emmanuelle Charpentier and Jennifer A. Doudna — The Nobel Foundation
- CRISPR Therapeutics pipeline and programs — CRISPR Therapeutics AG
- CRISPR Therapeutics Form 10-K Annual Report (most recent filing) — U.S. Securities and Exchange Commission
- Exagamglogene Autotemcel for Severe Sickle Cell Disease (Frangoul et al., NEJM) — The New England Journal of Medicine
- Vertex Pharmaceuticals and CRISPR Therapeutics collaboration overview — Vertex Pharmaceuticals
